TY  - JOUR
PY  - 2018//
TI  - Suicidal overdose of dolutegravir: A case report"
JO  - Southern African journal of HIV medicine
A1  - Daimari, R.
A1  - Kwape, L.
A1  - Oyekunle, A.A.
SP  - 
EP  - 
VL  - 19
IS  - 1
N2  - Dolutegravir (DTG) is the most recently introduced integrase inhibitor for the treatment of HIV infection and is preferred for its superior tolerability and efficacy in both new and pre- treated patients, and infrequent drug interactions. Since January 2017, Botswana has adopted a 'treat-air approach with a DTC-based antiretroviral (ARV) regimen as first-line treatment. We report a 29-year-old man with clinical stage 1 IIIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg of DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum creatinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect 2018. The Authors. © 2018 AOSIS (pty) Ltd. All rights reserved.<p /> <p>Language: en</p>
LA  - en
SN  - 1608-9693
UR  - http://dx.doi.org/10.4102/SAJHIVMED.V19I1.799
ID  - ref1
ER  -